Collaborating with Strategic Partners to Globally Advance the Development and Delivery of Our Targeted Immunotherapies
At Cue Biopharma, we are committed to bringing selective immune modulation to patients through our novel technology platforms and deliver immunotherapies with enhanced clinical efficacy and safety.
We work with the best researchers, clinicians and industry leaders through strategic collaborations and partnerships. Click on a collaborator below to learn more.
While our main focus is on advancing our oncology pipeline, we seek partnerships and licensing opportunities beyond cancer, for chronic infectious diseases and autoimmune diseases through the development of our promising platform technologies, Immuno-STAT™ (Selective Targeting and Alteration of T Cells), Neo-STAT™ and RDI-STAT™.
Cue Biopharma welcomes your interest in partnering opportunities.
For inquiries, please contact us at BD@cuebio.com.